Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Monitoring Changes in Plasma Proteome in AML Patients Receiving Blood Transfusion Products

Diana Muñoz Sandoval, Eva Smit, Iris charlotte Kreft, Carmen van Der Zwaan, Pieter Van Der Meer, Jan Voorberg, Paula F Ypma, Jean-Louis Kerkhoffs, Maartje Van Den Biggelaar

Blood (2023) 142 (Supplement 1): 2665.

https://doi.org/10.1182/blood-2023-180853

Published: 2023

Journal Articles

Characterization and Quantification of Von Willebrand Factor Proteoforms in Von Willebrand Disease Patients and Healthy Controls: Insights from the Win-Study

Iris charlotte Kreft, Tirsa T van Duijl, Calvin Van Kwawegen, Winny Phan, Margo Schuller, Carmen van Der Zwaan, Alexander Meijer, Ruben Bierings, Frank W.G. Leebeek, Maartje Van Den Biggelaar

Blood (2023) 142 (Supplement 1): 2606.

https://doi.org/10.1182/blood-2023-185987

Published: 2023

Journal Articles

Von Willebrand Factor Protects Factor VIII from Rapid Endocytosis Via LDL Receptor-Related Protein By Blocking the Initial Rate-Limiting Cell Surface Binding Step of Factor VIII

Henriet Meems, PhD, Carmen van der Zwaan, Koen Mertens, PhD, Alexander Meijer, PhD

Blood (2015) 126 (23): 214.

https://doi.org/10.1182/blood.V126.23.214.214

Published: 2015

Journal Articles

The N-Terminal Amino Acid Residues Ser764 and Lys773 of the D' Domain of Von Willebrand Factor Contribute to Factor VIII Binding

Lydia Castro-Núñez, Esther Bloem, Carmen van der Zwaan, Koen Mertens, PhD, Alexander B Meijer

Blood (2011) 118 (21): 2248.

https://doi.org/10.1182/blood.V118.21.2248.2248

Published: 2011

Journal Articles

LDL Receptor Mediates Effective Endocytosis of Activated Factor V.

Alexander B. Meijer, PhD, Sigrid D. Roosendaal, Vincent Limburg, Carmen van der Zwaan, Kees W. Rodenburg, Ph.D., Koen Mertens, Ph.D.

Blood (2007) 110 (11): 1766.

https://doi.org/10.1182/blood.V110.11.1766.1766

Published: 2007

Journal Articles

Effective Factor VIII Endocytosis Is under Conformational Control of von Willebrand Factor.

Alexander B. Meijer, PhD, Sigrid D. Roosendaal, Bas de Laat, Ph.D., Maartje van den Biggelaar, Vincent Limburg, Carmen van der Zwaan, Kees W. Rodenburg, Ph.D., Koen Mertens, Ph.D.

Blood (2007) 110 (11): 1767.

https://doi.org/10.1182/blood.V110.11.1767.1767

Published: 2007

NARROW

Monitoring Changes in Plasma Proteome in AML Patients Receiving Blood Transfusion Products

Characterization and Quantification of Von Willebrand Factor Proteoforms in Von Willebrand Disease Patients and Healthy Controls: Insights from the Win-Study

Von Willebrand Factor Protects Factor VIII from Rapid Endocytosis Via LDL Receptor-Related Protein By Blocking the Initial Rate-Limiting Cell Surface Binding Step of Factor VIII

The N-Terminal Amino Acid Residues Ser764 and Lys773 of the D' Domain of Von Willebrand Factor Contribute to Factor VIII Binding

LDL Receptor Mediates Effective Endocytosis of Activated Factor V.

Effective Factor VIII Endocytosis Is under Conformational Control of von Willebrand Factor.

Email alerts

ASH Publications

American Society of Hematology

Monitoring Changes in Plasma Proteome in AML Patients Receiving Blood Transfusion Products

Characterization and Quantification of Von Willebrand Factor Proteoforms in Von Willebrand Disease Patients and Healthy Controls: Insights from the Win-Study

Von Willebrand Factor Protects Factor VIII from Rapid Endocytosis Via LDL Receptor-Related Protein By Blocking the Initial Rate-Limiting Cell Surface Binding Step of Factor VIII

The N-Terminal Amino Acid Residues Ser764 and Lys773 of the D' Domain of Von Willebrand Factor Contribute to Factor VIII Binding

LDL Receptor Mediates Effective Endocytosis of Activated Factor V.

Effective Factor VIII Endocytosis Is under Conformational Control of von Willebrand Factor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only